Cargando…

Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning

We present the analysis of the defective genetic pathways of the Late-Onset Alzheimer’s Disease (LOAD) compared to the Mild Cognitive Impairment (MCI) and Healthy Controls (HC) using different sampling methodologies. These algorithms sample the uncertainty space that is intrinsic to any kind of high...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Martínez, Juan Luis, Álvarez-Machancoses, Óscar, deAndrés-Galiana, Enrique J., Bea, Guillermina, Kloczkowski, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279419/
https://www.ncbi.nlm.nih.gov/pubmed/32438758
http://dx.doi.org/10.3390/ijms21103594
_version_ 1783543557395578880
author Fernández-Martínez, Juan Luis
Álvarez-Machancoses, Óscar
deAndrés-Galiana, Enrique J.
Bea, Guillermina
Kloczkowski, Andrzej
author_facet Fernández-Martínez, Juan Luis
Álvarez-Machancoses, Óscar
deAndrés-Galiana, Enrique J.
Bea, Guillermina
Kloczkowski, Andrzej
author_sort Fernández-Martínez, Juan Luis
collection PubMed
description We present the analysis of the defective genetic pathways of the Late-Onset Alzheimer’s Disease (LOAD) compared to the Mild Cognitive Impairment (MCI) and Healthy Controls (HC) using different sampling methodologies. These algorithms sample the uncertainty space that is intrinsic to any kind of highly underdetermined phenotype prediction problem, by looking for the minimum-scale signatures (header genes) corresponding to different random holdouts. The biological pathways can be identified performing posterior analysis of these signatures established via cross-validation holdouts and plugging the set of most frequently sampled genes into different ontological platforms. That way, the effect of helper genes, whose presence might be due to the high degree of under determinacy of these experiments and data noise, is reduced. Our results suggest that common pathways for Alzheimer’s disease and MCI are mainly related to viral mRNA translation, influenza viral RNA transcription and replication, gene expression, mitochondrial translation, and metabolism, with these results being highly consistent regardless of the comparative methods. The cross-validated predictive accuracies achieved for the LOAD and MCI discriminations were 84% and 81.5%, respectively. The difference between LOAD and MCI could not be clearly established (74% accuracy). The most discriminatory genes of the LOAD-MCI discrimination are associated with proteasome mediated degradation and G-protein signaling. Based on these findings we have also performed drug repositioning using Dr. Insight package, proposing the following different typologies of drugs: isoquinoline alkaloids, antitumor antibiotics, phosphoinositide 3-kinase PI3K, autophagy inhibitors, antagonists of the muscarinic acetylcholine receptor and histone deacetylase inhibitors. We believe that the potential clinical relevance of these findings should be further investigated and confirmed with other independent studies.
format Online
Article
Text
id pubmed-7279419
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72794192020-06-17 Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning Fernández-Martínez, Juan Luis Álvarez-Machancoses, Óscar deAndrés-Galiana, Enrique J. Bea, Guillermina Kloczkowski, Andrzej Int J Mol Sci Article We present the analysis of the defective genetic pathways of the Late-Onset Alzheimer’s Disease (LOAD) compared to the Mild Cognitive Impairment (MCI) and Healthy Controls (HC) using different sampling methodologies. These algorithms sample the uncertainty space that is intrinsic to any kind of highly underdetermined phenotype prediction problem, by looking for the minimum-scale signatures (header genes) corresponding to different random holdouts. The biological pathways can be identified performing posterior analysis of these signatures established via cross-validation holdouts and plugging the set of most frequently sampled genes into different ontological platforms. That way, the effect of helper genes, whose presence might be due to the high degree of under determinacy of these experiments and data noise, is reduced. Our results suggest that common pathways for Alzheimer’s disease and MCI are mainly related to viral mRNA translation, influenza viral RNA transcription and replication, gene expression, mitochondrial translation, and metabolism, with these results being highly consistent regardless of the comparative methods. The cross-validated predictive accuracies achieved for the LOAD and MCI discriminations were 84% and 81.5%, respectively. The difference between LOAD and MCI could not be clearly established (74% accuracy). The most discriminatory genes of the LOAD-MCI discrimination are associated with proteasome mediated degradation and G-protein signaling. Based on these findings we have also performed drug repositioning using Dr. Insight package, proposing the following different typologies of drugs: isoquinoline alkaloids, antitumor antibiotics, phosphoinositide 3-kinase PI3K, autophagy inhibitors, antagonists of the muscarinic acetylcholine receptor and histone deacetylase inhibitors. We believe that the potential clinical relevance of these findings should be further investigated and confirmed with other independent studies. MDPI 2020-05-19 /pmc/articles/PMC7279419/ /pubmed/32438758 http://dx.doi.org/10.3390/ijms21103594 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fernández-Martínez, Juan Luis
Álvarez-Machancoses, Óscar
deAndrés-Galiana, Enrique J.
Bea, Guillermina
Kloczkowski, Andrzej
Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning
title Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning
title_full Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning
title_fullStr Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning
title_full_unstemmed Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning
title_short Robust Sampling of Defective Pathways in Alzheimer’s Disease. Implications in Drug Repositioning
title_sort robust sampling of defective pathways in alzheimer’s disease. implications in drug repositioning
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279419/
https://www.ncbi.nlm.nih.gov/pubmed/32438758
http://dx.doi.org/10.3390/ijms21103594
work_keys_str_mv AT fernandezmartinezjuanluis robustsamplingofdefectivepathwaysinalzheimersdiseaseimplicationsindrugrepositioning
AT alvarezmachancosesoscar robustsamplingofdefectivepathwaysinalzheimersdiseaseimplicationsindrugrepositioning
AT deandresgalianaenriquej robustsamplingofdefectivepathwaysinalzheimersdiseaseimplicationsindrugrepositioning
AT beaguillermina robustsamplingofdefectivepathwaysinalzheimersdiseaseimplicationsindrugrepositioning
AT kloczkowskiandrzej robustsamplingofdefectivepathwaysinalzheimersdiseaseimplicationsindrugrepositioning